Compound: Eltoprazine
SMILES: O1c2c(OCC1)cccc2N3CCNCC3
InChIKey: WVLHGCRWEHCIOT-UHFFFAOYSA-N
Synonyms: Eltoprazine, 98224-03-4, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)piperazine, Eltoprazina, Eltoprazinum, DU-28853, 510M006KO6, DTXSID5048425, RefChem:136558, DTXCID3028398, 872-479-1, 1-(2,3-Dihydrobenzo[b][1,4]dioxin-5-yl)piperazine, 1-(2,3-Dihydro-benzo[1,4]dioxin-5-yl)-piperazine, Eltoprazine [INN], 1-(1,4-Benzodioxan-5-yl)piperazine, MFCD00868056, CHEMBL282614, 4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazine, DU 28853, Eltoprazinum [Latin], Eltoprazina [Spanish], NCGC00159533-01, ELTOPRAZINE [MI], ELTOPRAZINE [MART.], 1-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazine, SCHEMBL177715, orb1692272, SCHEMBL2203340, N-(benzodioxan-5-yl)piperazine, UNII-510M006KO6, CHEBI:234413, 1-(1,4-benzodioxan-5-yl)piperazin, BDBM50035057, EBC-71126, PDSP1_000561, PDSP2_000559, AKOS016007669, 1-(1,4-benzodioxan-5-yl)-piperazine, CS-3216, DB12883, FE22657, SB16767, DU 28893, HY-16687, NS00068070, (2,3-dihydro[1,4]benzodioxin-5-yl)piperazine, H11026, EN300-1839382, 1-(2,3-dihydro-1,4-benzodioxan-5-yl)piperazine, L000982, N-(2,3-dihydrobenzo[1,4]dioxin-5-yl)piperazine, 1-(2,3-dihydrobenzo[1,4]dioxin-5-yl)-piperazine, 4-(2,3-dihydrobenzo[1,4]dioxin-5-yl)-piperazine, Q5367896, 4-(2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazine, 4-(2,3-dihydro-benzo[1,4]dioxin-5-yl)-piperazine, BRD-K86171477-001-01-3, BRD-K86171477-001-02-1, BRD-K86171477-001-03-9, BRD-K86171477-003-01-9, Z2044804716, (eltoprazine)1-(2,3-Dihydro-benzo[1,4]dioxin-5-yl)-piperazine
Theoretical properties:
molecular_formula: C12H16N2O2
molecular_weight: 220.27 g/mol
exact_mass: 220.121177757 g/mol
formal_charge: 0
hydrogen_bond_donor_count: 1
hydrogen_bond_acceptor_count: 4
rotatable_bond_count: 1
heavy_atom_count: 16
topological_polar_surface_area: 33.7 Å²
isotope_atom_count: 0
covalently_bonded_unit_count: 1
Physical properties:
Descriptions:
{"pubchem": "Eltoprazine is a member of the class of piperazines that is 1,4-benzodioxane substituted by a piperazin-1-yl group at position 5. It exhibits strong antidyskinetic effects and was previously in clinical trials for the management of aggressive behaviours. It has a role as an anxiolytic drug, a serotonergic agonist and an antidyskinesia agent. It is a member of piperazines, a tertiary amino compound and a benzodioxine.", "chebi": "A member of the class of piperazines that is 1,4-benzodioxane substituted by a piperazin-1-yl group at position 5. It exhibits strong antidyskinetic effects and was previously in clinical trials for the management of aggressive behaviours.", "chembl": "ELTOPRAZINE is a small molecule listed in the ChEMBL database and has reached clinical trial phase 2.0.", "wikipedia": "Eltoprazine (INNTooltip International Nonproprietary Name; developmental code name DU-28,853) is a non-selective serotonin receptor modulator of the phenylpiperazine family which was under development for the treatment of aggression, attention deficit hyperactivity disorder (ADHD), cognition disorders, drug-induced dyskinesia, and psychotic disorders but was never marketed. It has been described as a \"serenic\" or antiaggressive agent. The drug is taken orally.\nIt acts as an agonist of the serotonin 5-HT1A and 5-HT1B receptors and as an antagonist of the serotonin 5-HT2C receptor (Ki = 40 nM, 52 nM, and 81 nM, respectively). The drug also shows weaker affinity for certain other serotonin receptors and targets. The pharmacokinetics of eltoprazine have been studied. Eltoprazine is closely related to fluprazine and batoprazine, which are similarly acting agents, and is also a known chemical precursor to S-15535 and lecozotan.\nEltoprazine was first described in the scientific literature by 1987. It was originated by Solvay and was developed by Elto Pharma, PsychoGenics, and Solvay. The drug is or was under development for the treatment of aggression, ADHD, cognitive disorders, and drug-induced dyskinesia, but no recent development has been reported for these indications as of 2022. It was also under development for the treatment of psychotic disorders, but development for this indication was discontinued. Eltoprazine reached phase 2 or 3 clinical trials. According to David Nutt, eltoprazine showed shown signs of effectiveness in the treatment of aggression but was rejected for marketing authorization on the basis of aggression being a symptom rather than a disorder."}